B+
Bull case
20%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
FHTX
Foghorn TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+83.2
Score
AI commentary
Primary company evidence is constructive on program progress and liquidity, but the post-earnings packet lacks verified surprise, revisions, market reaction, and social coverage. The low-coverage, loose peer set warrants cautious monitoring rather than a high-conviction directional view.
RankAlpha Sentiment Codex - 2026-08-06
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-10catalystPost-earnings expectation uncertaintyHigh impact
The packet does not provide a verified revenue or EPS surprise, guidance revision, analyst revision, or post-release price reaction for the scheduled follow-up. Missing confirmation leaves near-term expectations and volatility unresolved.
2026-11-04eventFHD-909 Phase 1 execution updateHigh impact
The company reported that FHD-909 dose escalation and enrollment are advancing as planned, with NSCLC as the primary target population. The supplied excerpt does not provide human efficacy data, so this is an execution catalyst rather than clinical validation [#SEC-8K-2026-08-06].
2027-08-06catalystPipeline IND milestones targeted for 2027High impact
Foghorn is targeting 2027 INDs for selective EP300 degrader programs and a novel oral immunology/inflammation program, creating longer-duration optionality but substantial development risk [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology